Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome

被引：37

作者：

Dupont, Allison G. ^{[1
]}

Gabriel, Don A.

Cohen, Mauricio G.

机构：

[1] Univ N Carolina, Dept Med, Div Cardiol, Chapel Hill, NC 27599 USA

来源：

THROMBOSIS RESEARCH | 2009年 / 124卷 / 01期

关键词：

Antiplatelet drugs; Antiplatelet resistance; Acute coronary syndrome; ACUTE MYOCARDIAL-INFARCTION; HIGH-RISK PATIENTS; ASPIRIN RESISTANCE; UNSTABLE ANGINA; RANDOMIZED EVALUATION; CLINICAL-OUTCOMES; CLOPIDOGREL; ABCIXIMAB; RECEPTOR; INTERVENTION;

D O I：

10.1016/j.thromres.2009.01.014

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Acute coronary syndrome is the number one killer in the industrialized world and, as such, continues to be one of the most well-studied disease states in all of medicine. Advancements in antiplatelet therapies for use in patients undergoing percutaneous coronary intervention have improved outcomes dramatically. However, a proportion of patients on long-term antiplatelet therapy continue to have cardiovascular events. Resistance to antiplatelet drugs may explain some of these events and this topic has become one of major interest and rapid evolution. This review describes the pathogenesis of acute coronary syndromes, outlines the evidence behind the use of the available antiplatelet agents, and examines the current data surrounding antiplatelet resistance. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：6 / 13

页数：8

共 69 条

[1] Recent antiplatelet drug trials in the acute coronary syndromes - Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT [J].

Alexander, JH ;

Harrington, RA .

DRUGS, 1998, 56 (06) :965-976

[2] ACC/AHA 2007 guide lines for the management of patients with unstable Angina/Non-ST-Elevation myocardial infraction - Executive summary [J].

Anderson, Jeffrey L. ;

Adams, Cynthia D. ;

Antman, Elliott M. ;

Bridges, Charles R. ;

Califf, Robert M. ;

Casey, Donald E., Jr. ;

Chavey, William E., II ;

Fesmire, Francis M. ;

Hochman, Judith S. ;

Levin, Thomas N. ;

Lincoff, A. Michael ;

Peterson, Eric D. ;

Theroux, Pierre ;

Wenger, Nanette Kass ;

Wright, R. Scott ;

Smith, Sidney C., Jr. ;

Jacobs, Alice K. ;

Adams, Cynthia D. ;

Riegel, Barbara .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (07) :652-726

[3]

Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71

[4]

Bazzino O, 1998, NEW ENGL J MED, V338, P1498

[5]

Bazzino O, 1998, NEW ENGL J MED, V338, P1488

[6] Early abciximab administration in acute myocardial infarction treated with primary coronary intervention [J].

Bellandi, F ;

Maioli, M ;

Leoncini, M ;

Toso, A ;

Dabizzi, RP .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 108 (01) :36-42

[7] Novel platelet inhibitors [J].

Bennett, JS .

ANNUAL REVIEW OF MEDICINE, 2001, 52 :161-184

[8] Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting - The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study [J].

Bertrand, ME ;

Legrand, V ;

Boland, J ;

Fleck, E ;

Bonnier, J ;

Emmanuelson, H ;

Vrolix, M ;

Missault, L ;

Chierchia, S ;

Casaccia, M ;

Niccoli, L ;

Oto, A ;

White, C ;

Webb-Peploe, M ;

Van Belle, E ;

McFadden, EP .

CIRCULATION, 1998, 98 (16) :1597-1603

[9]

BONELLO L, 2008, SCAI ACC I2 SUMM AM

[10] ASPIRIN, SULFINPYRAZONE, OR BOTH IN UNSTABLE ANGINA - RESULTS OF A CANADIAN MULTICENTER TRIAL [J].

CAIRNS, JA ;

GENT, M ;

SINGER, J ;

FINNIE, KJ ;

FROGGATT, GM ;

HOLDER, DA ;

JABLONSKY, G ;

KOSTUK, WJ ;

MELENDEZ, LJ ;

MYERS, MG ;

SACKETT, DL ;

SEALEY, BJ ;

TANSER, PH .

NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (22) :1369-1375

← 1 2 3 4 5 6 7 →